Edition:
United States

Curis Inc (CRIS.OQ)

CRIS.OQ on NASDAQ Stock Exchange Global Market

3.08USD
8 Dec 2016
Change (% chg)

-- (--)
Prev Close
$3.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
136,005
52-wk High
$3.71
52-wk Low
$1.25

CRIS.OQ

Chart for CRIS.OQ

About

Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.... (more)

Overall

Beta: 1.90
Market Cap(Mil.): $432.89
Shares Outstanding(Mil.): 140.55
Dividend: --
Yield (%): --

Financials

  CRIS.OQ Industry Sector
P/E (TTM): -- 41.20 30.65
EPS (TTM): -0.48 -- --
ROI: -83.10 -0.59 15.23
ROE: -109.85 -1.31 16.56

BRIEF-Curis says announces full approval of Roche's Erivedge in European Union

* Says announces full approval of Roche's Erivedge in European Union

Nov 28 2016

BRIEF-Curis reports appointment of Lori Kunkel to board of directors

* Curis announces appointment of Lori A. Kunkel, m.d. to board of directors Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Curis Q3 loss per share $0.21

* Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-Curis says Aurigene to invest in co through waiver of payments under collaboration deal

* Aurigene to invest in Curis at premium through waiver of certain milestone payments under collaboration agreement

Sep 07 2016

BRIEF-Curis Q2 loss per share $0.09

* Q2 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Aug 04 2016

Earnings vs. Estimates